Fluticasone Propionate (Page 2 of 3)
Adverse Reactions
Clinical Trial Experience –
In controlled clinical trials of twice-daily administration, the total incidence of adverse reactions associated with the use of fluticasone propionate cream, 0.05% was approximately 4%. These adverse reactions were usually mild; self-limiting; and consisted primarily of pruritus, dryness, numbness of fingers, and burning. These events occurred in 2.9%, 1.2%, 1.0%, and 0.6% of patients, respectively.
Two clinical studies compared once- to twice-daily administration of fluticasone propionate cream, 0.05% for the treatment of moderate to severe eczema. The local drug-related adverse events for the 491 patients enrolled in both studies are shown in Table 1. In the study enrolling both adult and pediatric patients, the incidence of local adverse events in the 119 pediatric patients ages 1 to 12 years was comparable to the 140 patients ages 13 to 62 years.
Fifty-one pediatric patients ages 3 months to 5 years, with moderate to severe eczema, were enrolled in an open-label HPA axis safety study. Fluticasone propionate cream, 0.05% was applied twice daily for 3 to 4 weeks over an arithmetic mean body surface area of 64% (range, 35% to 95%). The mean morning cortisol levels with standard deviations before treatment (prestimulation mean value = 13.76 ± 6.94 mcg/dL, poststimulation mean value = 30.53 ± 7.23 mcg/dL) and at end treatment (prestimulation mean value = 12.32 ± 6.92 mcg/dL, poststimulation mean value = 28.84 ± 7.16 mcg/dL) showed little change. In 2 of 43 (4.7%) patients with end-treatment results, peak cortisol levels following cosyntropin stimulation testing were ≤18 μg/dL, indicating adrenal suppression. Follow-up testing after treatment discontinuation, available for 1 of the 2 subjects, demonstrated a normally responsive HPA axis. Local drug-related adverse events were transient burning, resolving the same day it was reported; transient urticaria, resolving the same day it was reported; erythematous rash; dusky erythema, resolving within 1 month after cessation of fluticasone propionate cream, 0.05%; and telangiectasia, resolving within 3 months after stopping fluticasone propionate cream, 0.05%.
Table 1: Drug-Related Adverse Events-Skin
Adverse Events
Fluticasone Once Daily (n = 210)
Fluticasone Twice Daily (n = 203)
Vehicle Twice Daily
(n = 78)
Skin infection
Infected eczema
Viral warts
Herpes simplex
Impetigo
Atopic dermatitis
Eczema
Exacerbation of eczema
Erythema
Burning
Stinging
Skin irritation
Pruritus
Exacerbation of pruritus
Folliculitis
Blisters
Dryness of skin
1 (0.5%)
1 (0.5%)
0
0
1 (0.5%)
1 (0.5%)
1 (0.5%)
4 (1.9%)
0
2 (1.0%)
0
6 (2.9%)
2 (1.0%)
4 (1.9%)
1 (0.5%)
0
3 (1.4%)
0
2 (1.0%)
1 (0.5%)
1 (0.5%)
0
0
0
1 (0.5%)
2 (1.0%)
2 (1.0%)
2 (1.0%)
2 (1.0%)
4. (1.9%)
1 (0.5%)
1 (0.5%)
1 (0.5%)
1 (0.5%)
0
0
0
0
0
0
0
1 (1.3%)
0
2 (2.6%)
1 (1.3%)
0
4 (5.1%)
1 (1.3%)
0
0
0
Table 2: Adverse Events* From Pediatric Open-Label Trial (n=51)
Adverse Events
Fluticasone Twice Daily
Burning
Dusky erythema
Erythematous rash
Facial telangiectasia†
Non-facial telangiectasia
Urticaria
1 (2.0%)
1 (2.0%)
1 (2.0%)
2 (4.9%)
1 (2.0%)
1 (2.0%)
* See text for additional detail.
† n=41.
Post Marketing Experience –
Systemic adverse events with fluticasone propionate cream, 0.05% and fluticasone propionate ointment have included: immunosuppression/Pneumocystis carinii pneumonia/leukopenia/thrombocytopenia; hyperglycemia/glycosuria; Cushing’s syndrome; generalized body edema/blurred vision; and acute urticarial reaction (edema, urticaria, pruritus, and throat swelling).
The following localized adverse reactions have been reported during post approval use of fluticasone propionate cream, 0.05%: skin discoloration, erythema, irritation, edema/swelling, atrophy, contusion, dermatitis, pain, sepsis, hemorrhage, acneiform eruptions.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Overdosage
Topically applied Fluticasone Propionate Cream, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
Dosage & Administration
Fluticasone Propionate Cream, 0.05% may be used in adult and pediatric patients 3 months of age or older. Safety and efficacy of Fluticasone Propionate Cream, 0.05% in pediatric patients for more than 4 weeks of use have not been established (see PRECAUTIONS — PEDIATRIC USE). The safety and efficacy of Fluticasone Propionate Cream, 0.05% in pediatric patients below 3 months of age have not been established.
Atopic Dermatitis –
Apply a thin film of Fluticasone Propionate Cream, 0.05% to the affected skin areas once or twice daily. Rub in gently.
Other Corticosteroid-Responsive Dermatoses –
Apply a thin film of Fluticasone Propionate Cream, 0.05% to the affected skin areas twice daily. Rub in gently.
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Fluticasone Propionate Cream, 0.05% should not be used with occlusive dressings. Fluticasone Propionate Cream, 0.05% should not be applied in the diaper area, as diapers or plastic pants may constitute occlusive dressings.
Geriatric Use –
In studies where geriatric patients (65 years of age or older, see PRECAUTIONS) have been treated with fluticasone propionate cream, 0.05%, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.
Clinical Studies
Psoriasis Studies –
In 2 vehicle-controlled studies, fluticasone propionate cream, 0.05% applied twice daily was significantly more effective than the vehicle in the treatment of moderate to severe psoriasis. The investigator’s global evaluation after 28 days of treatment is shown in Table 3.
Table 3: Physician’s Assessment of Clinical Response
Fluticasone propionate cream, 0.05%
Vehicle
Study 1
(n = 59)
Study 2
(n = 74)
Study 1
(n = 66)
Study 2
(n = 75)
Cleared
Excellent
Good
Fair
Poor
Worse
8%
29%
27%
27%
7%
2%
1%
28%
34%
15%
22%
0
3%
11%
20%
33%
24%
9%
1%
17%
28%
25%
27%
1%
The clinical signs of psoriasis were scored on a scale of 0=absent, 1=mild, 2=moderate, and 3=severe. The mean improvements over baseline in the clinical signs at the end of treatment are shown in Table 4.
Table 4: Clinical Signs: Mean Improvements Over Baseline
Fluticasone propionate cream, 0.05%
Vehicle
Study 1
Study 2
Study 1
Study 2
Erythema
Thickening
Scaling
1.19
1.22
1.53
1.07
1.17
1.39
0.55
0.81
0.95
0.84
0.97
1.21
Atopic Dermatitis Studies –
In 2 controlled 28-day studies, fluticasone propionate cream, 0.05% once daily was equivalent to fluticasone propionate cream, 0.05% twice daily in the treatment of moderate to severe eczema. The investigator’s global evaluation after 28 days of treatment is shown in Table 5.
Table 5: Physician’s Assessment of Clinical Response
Fluticasone propionate cream, 0.05%, Once Daily
Fluticasone propionate cream, 0.05%, Twice Daily
Study 1
(n = 64)
Study 2
(n = 106)
Study 1
(n = 65)
Study 2
(n = 100)
Cleared
Excellent
Good
Fair
Poor
Worse
30%
42%
17%
3%
5%
3%
20%
32%
26%
14%
3%
6%
48%
32%
5%
6%
8%
2%
21%
50%
12%
10%
4%
3%
The clinical signs and symptoms of atopic dermatitis were scored on a scale of 0=absent, 1=mild, 2=moderate, and 3=severe. The mean improvements over baseline at the end of treatment are shown in Table 6.
Table 6: Clinical Signs and Symptoms: Mean Improvements Over Baseline
Fluticasone propionate cream, 0.05%, Once Daily
Fluticasone propionate cream, 0.05%, Twice Daily
Study 1
Study 2
Study 1
Study 2
Erythema
Pruritus
Thickening
Lichenification
Vesiculation
Crusting
1.7
2.1
1.6
1.2
0.5
0.6
1.5
1.6
1.3
1.2
0.4
0.7
1.8
2.1
1.6
1.2
0.5
0.8
1.7
1.7
1.5
1.3
0.5
0.8
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/fluticasone-propionate/page/2/